SGLT-2 inhibitors, including empagliflozin, canagliflozin, and dapagliflozin, are relatively new antidiabetic agents that provenly reduce major cardiovascular complications, hospital admission in heart failure patients, and the advancement of CKD in patients with T2DM and obesity. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.